Fenwick & West has represented Nava Benefits. Alliant Insurance Services has entered into an agreement to acquire Nava Benefits, a provider of employee benefits brokerage services....
Alliant Insurance Services to Acquire Nava Benefits
iRhythm to Acquire VitalConnect in $287.5 Million Digital Health Deal
Fenwick & West has advised iRhythm Holdings. Goodwin Procter has advised VitalConnect. iRhythm Holdings, Inc. (Nasdaq: IRTC), a digital healthcare company specializing in solutions for disease...
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
Merger Agreement Between Treeline Biosciences and Standard BioTools
Freshfields LLP and Richards, Layton & Finger, P.A. have advised Standard BioTools. Fenwick & West LLP has represented Treeline Biosciences. Treeline Biosciences and Standard BioTools Inc....
Servier to Acquire Day One Biopharmaceuticals in $2.5 Billion Transaction
Baker McKenzie has advised Servier, and Fenwick & West has advised Day One Biopharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related...
Halozyme Acquires Surf Bio in $400 Million Deal to Expand Drug Delivery Capabilities
Fenwick & West has advised Surf Bio on the deal. Surf Bio, a biopharmaceutical company specializing in innovative drug delivery technologies, has been acquired by Halozyme...
Day One Biopharmaceuticals to Acquire Mersana Therapeutics in Transaction Valued Up to $285 Million
Wilmer Cutler Pickering Hale and Dorr has advised Mersana Therapeutics. Fenwick & West has advised Day One Biopharmaceuticals. Wilson Sonsini Goodrich & Rosati advised Day One...
Figma Announces $1.2 Billion Initial Public Offering
Fenwick has advised Figma on the offering, Latham & Watkins has advised the underwriters. Whalen LLP has acted as counsel for the selling stockholders. Figma, a...
Formation Bio Enters Licensing Agreement with Sanofi for Gusacitinib
Fenwick has advised Formation Bio on the deal. Formation Bio, an AI-native drug development company, has entered into a licensing agreement with Sanofi, a French multinational...
GeneDX’s Acquisition of Fabric Genomics
Fenwick & West represented GeneDX in the transaction, and DLA Piper advised Fabric Genomics, Inc. GeneDX (Nasdaq: WGS), a company delivering improved health outcomes through genomic...
Stoke Therapeutics’ Collaboration with BioGen
Fenwick & West represented Stoke Therapeutics, Inc. in the transaction. Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the...
ACELYRIN’s Merger with Alumis
Fenwick & West and Paul Hastings advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company...